Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Circulating TNF Receptors 1 and 2 Predict the Progression of Diabetic Kidney Disease: A Meta-analysis.

Ye X, Luo T, Wang K, Wang Y, Yang S, Li Q, Hu J.

Diabetes Metab Res Rev. 2019 Jun 17:e3195. doi: 10.1002/dmrr.3195. [Epub ahead of print]

PMID:
31207020
2.

Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease.

Coca SG, Nadkarni GN, Huang Y, Moledina DG, Rao V, Zhang J, Ferket B, Crowley ST, Fried LF, Parikh CR.

J Am Soc Nephrol. 2017 Sep;28(9):2786-2793. doi: 10.1681/ASN.2016101101. Epub 2017 May 5.

3.

Multidisciplinary management of diabetic kidney disease: a systematic review and meta-analysis.

Helou N, Dwyer A, Shaha M, Zanchi A.

JBI Database System Rev Implement Rep. 2016 Jul;14(7):169-207. doi: 10.11124/JBISRIR-2016-003011. Review.

PMID:
27532796
4.

Vitamin B and its derivatives for diabetic kidney disease.

Raval AD, Thakker D, Rangoonwala AN, Gor D, Walia R.

Cochrane Database Syst Rev. 2015 Jan 12;1:CD009403. doi: 10.1002/14651858.CD009403.pub2. Review.

PMID:
25579852
5.

Pentoxifylline for diabetic kidney disease.

Shan D, Wu HM, Yuan QY, Li J, Zhou RL, Liu GJ.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD006800. doi: 10.1002/14651858.CD006800.pub2. Review.

PMID:
22336824
6.

Tissue expression of tubular injury markers is associated with renal function decline in diabetic nephropathy.

Hwang S, Park J, Kim J, Jang HR, Kwon GY, Huh W, Kim YG, Kim DJ, Oh HY, Lee JE.

J Diabetes Complications. 2017 Dec;31(12):1704-1709. doi: 10.1016/j.jdiacomp.2017.08.009. Epub 2017 Aug 24.

PMID:
29037450
7.

A study of the natural history of diabetic kidney disease (DKD).

Altemtam N, Russell J, El Nahas M.

Nephrol Dial Transplant. 2012 May;27(5):1847-54. doi: 10.1093/ndt/gfr561. Epub 2011 Nov 5.

PMID:
22058177
8.

Clinical predictive biomarkers for normoalbuminuric diabetic kidney disease.

Gohda T, Nishizaki Y, Murakoshi M, Nojiri S, Yanagisawa N, Shibata T, Yamashita M, Tanaka K, Yamashita Y, Suzuki Y, Kamei N.

Diabetes Res Clin Pract. 2018 Jul;141:62-68. doi: 10.1016/j.diabres.2018.04.026. Epub 2018 May 3.

PMID:
29729375
9.

Associations of urinary epidermal growth factor and monocyte chemotactic protein-1 with kidney involvement in patients with diabetic kidney disease.

Wu L, Li XQ, Chang DY, Zhang H, Li JJ, Wu SL, Zhang LX, Chen M, Zhao MH.

Nephrol Dial Transplant. 2018 Oct 23. doi: 10.1093/ndt/gfy314. [Epub ahead of print]

PMID:
30357416
10.

Urinary matrix metalloproteinase activity in diabetic kidney disease: a potential marker of disease progression.

Altemtam N, Nahas ME, Johnson T.

Nephron Extra. 2012 Jan;2:219-32. doi: 10.1159/000339645. Epub 2012 Aug 9.

11.

Association between the ENPP1 K121Q polymorphism and risk of diabetic kidney disease: a systematic review and meta-analysis.

Sortica DA, Buffon MP, Souza BM, Nicoletto BB, Santer A, Assmann TS, Crispim D, Canani LH.

PLoS One. 2015 Mar 20;10(3):e0118416. doi: 10.1371/journal.pone.0118416. eCollection 2015. Review.

12.

Antihypertensive agents for preventing diabetic kidney disease.

Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD004136. doi: 10.1002/14651858.CD004136.pub3. Review.

PMID:
23235603
13.

Circulating Tumor Necrosis Factor α Receptors Predict the Outcomes of Human IgA Nephropathy: A Prospective Cohort Study.

Oh YJ, An JN, Kim CT, Yang SH, Lee H, Kim DK, Joo KW, Paik JH, Kang SW, Park JT, Lim CS, Kim YS, Lee JP.

PLoS One. 2015 Jul 15;10(7):e0132826. doi: 10.1371/journal.pone.0132826. eCollection 2015.

14.

Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease.

Liu JJ, Ghosh S, Kovalik JP, Ching J, Choi HW, Tavintharan S, Ong CN, Sum CF, Summers SA, Tai ES, Lim SC.

Kidney Int Rep. 2016 Dec 16;2(3):470-480. doi: 10.1016/j.ekir.2016.12.003. eCollection 2017 May.

15.

Plasma Leucine-Rich α-2-Glycoprotein 1 Predicts Rapid eGFR Decline and Albuminuria Progression in Type 2 Diabetes Mellitus.

Liu JJ, Pek SLT, Ang K, Tavintharan S, Lim SC; SMART2D study.

J Clin Endocrinol Metab. 2017 Oct 1;102(10):3683-3691. doi: 10.1210/jc.2017-00930.

PMID:
28973352
16.

Prostaglandin E1 for preventing the progression of diabetic kidney disease.

Wang H, Deng JL, Yue J, Li J, Hou YB.

Cochrane Database Syst Rev. 2010 May 12;(5):CD006872. doi: 10.1002/14651858.CD006872.pub2. Review.

PMID:
20464745
17.

Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.

Feng Y, Huang R, Kavanagh J, Li L, Zeng X, Li Y, Fu P.

Am J Cardiovasc Drugs. 2019 Jun;19(3):259-286. doi: 10.1007/s40256-018-00321-5. Review.

PMID:
30737754
18.

Aortic stiffness and ambulatory blood pressure as predictors of diabetic kidney disease: a competing risks analysis from the Rio de Janeiro Type 2 Diabetes Cohort Study.

Cardoso CRL, Leite NC, Salles GC, Ferreira MT, Salles GF.

Diabetologia. 2018 Feb;61(2):455-465. doi: 10.1007/s00125-017-4484-z. Epub 2017 Oct 23.

PMID:
29063128
19.

Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease.

Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006257. Review.

PMID:
17054288
20.

The Association between Obstructive Sleep Apnea on Diabetic Kidney Disease: A Systematic Review and Meta-Analysis.

Leong WB, Jadhakhan F, Taheri S, Thomas GN, Adab P.

Sleep. 2016 Feb 1;39(2):301-8. doi: 10.5665/sleep.5432. Review.

Supplemental Content

Support Center